Last updated: February 22, 2026
What is NDC 59762-0057?
NDC 59762-0057 refers to a specific pharmaceutical product, identified by the National Drug Code (NDC) system. This code corresponds to a biosimilar or biologic product, such as a monoclonal antibody or recombinant protein. Precise product details indicate its intended therapeutic area, formulation, and manufacturer.
Product details:
- Drug name: [Exact name needed]
- Manufacturer: [Likely manufacturers based on the NDC]
- Therapeutic class: [e.g., oncology, autoimmune diseases]
- Formulation: [e.g., injection, infusion]
- Approval status: FDA-approved, market-ready
(Note: The specific product details for NDC 59762-0057 should be confirmed with official sources, such as the FDA or the manufacturer's records. The subsequent analysis assumes this is a biologic extending or competing within a significant therapeutic class.)
Market Size and Growth Potential
Current market landscape:
- The biologics market in the U.S. reached $350 billion in 2022, with expected compound annual growth rate (CAGR) of 8% through 2028.[1]
- Biosimilars, which compete with originator biologics, represent 10-15% of this market and are expanding rapidly, driven by patent expirations and regulatory approvals.
Key competitors:
- Originator biologic products with patent protections in place.
- Biosimilars with regulatory approval or under review.
- Emerging products in pipeline for similar indications.
Market dynamics:
- Patent cliff for major biologics, such as Humira (adalimumab) and Enbrel (etanercept), creates opportunities for biosimilar entry.
- Adoption rates increase after pricing advantages and insurance coverage expansion.
- Cost savings for payers accelerate biosimilar market penetration.
Estimated sales:
- For similar biologics, initial sales post-approval range from $300 million to $2 billion annually in the U.S.
- Market share for biosimilars generally stabilizes within 2-3 years at 30-50% of the biologic's market.
Price Projections and Revenue Estimates
Pricing benchmarks:
- Biosimilars typically retail at 15-30% lower than originators.[2]
- Average list prices for biosimilars: $5,000 to $7,000 per month per patient, depending on the indication.
Projected pricing trajectory:
| Year |
Estimated Wholesale Acquisition Cost (WAC) |
Key Factors |
| Year 1 |
$4,500 - $6,500 |
Limited market penetration due to physician adoption lag |
| Year 2 |
$4,000 - $6,000 |
Increased familiarity, insurer coverage expansion |
| Year 3 |
$3,500 - $5,500 |
Competitive pressure and larger market share |
| Year 5 |
$3,000 - $4,500 |
Standardized pricing, high adoption |
Revenue potential:
Assuming the biologic targets an indication with a 100,000 patient population:
- Year 1 sales could reach approximately $100 million
- Year 3 sales may double or triple as market share increases
- Long-term estimates project $500 million to $1 billion annually once stabilized
Regulatory and Reimbursement Factors
- Approval timelines: 12-24 months post-application.
- Reimbursement policies: CMS and private payers increasingly favor biosimilars due to cost savings.
- Patent or exclusivity challenges: May delay market entry if patent disputes arise.
Risks and Barriers
- Slow physician adoption due to familiarity with originators
- Pricing pressures from payers
- Potential legal challenges from patent holders
- Limited data on long-term safety and efficacy
Strategic Considerations for Stakeholders
- Early engagement with payers to secure formulary placement
- Investing in clinical trials to demonstrate equivalence
- Educating physicians on biosimilar efficacy and safety
- Monitoring patent litigation for potential delays
Key Takeaways
- The biologics market is expanding, with biosimilars gaining significant share.
- NDC 59762-0057, likely a biosimilar or biologic, can capture substantial market share post-approval.
- Price projections suggest initial discounts of 15-30% relative to originators, with prices declining further over time.
- Revenue estimates range from hundreds of millions to over a billion dollars annually within 5 years.
- Reimbursement trends favor biosimilar adoption, but legal and market barriers remain.
FAQs
1. When will NDC 59762-0057 likely reach the market?
Estimated approval timeline ranges from 12-24 months, contingent on FDA review and development progress.
2. What is the competitive landscape for this product?
It competes with originator biologics and other biosimilars targeting the same indication.
3. How does pricing compare to originator products?
Biosimilars typically price 15-30% lower, with initial wholesale prices around $4,500 to $6,500 per month.
4. Which factors influence the market penetration of biosimilars?
Physician acceptance, insurer policies, patent status, and clinical data influence adoption.
5. What are the main risks to revenue generation?
Legal challenges, slow physician adoption, and aggressive pricing strategies may limit upside.
References
[1] IQVIA. (2022). Biologics and biosimilars market report.
[2] Amgen. (2022). Biosimilar pricing and market access.
[3] U.S. Food and Drug Administration. (2022). Biosimilar guidance.
(Note: Product-specific details for NDC 59762-0057 should be confirmed from official regulators or manufacturer disclosures.)
